European agents like IOP-lowering drug

April 1, 2006

Fort Worth, TX?The European Medicines Agency's Committee for Medicinal Products for Human Use has reacted positively to the initial marketing authorization for Alcon Laboratories' travoprost 0.004%/ timolol 0.5% solution (DuoTrav) for lowering IOP.

Fort Worth, TX-The European Medicines Agency's Committee for Medicinal Products for Human Use has reacted positively to the initial marketing authorization for Alcon Laboratories' travoprost 0.004%/ timolol 0.5% solution (DuoTrav) for lowering IOP.

In a statement, Alcon said the approval sets the stage for marketing authorization of the solution within Europe. The authorization could be finalized during the second quarter of 2006, the company said.

The solution, administered as one drop daily, combines a beta blocker to decrease the production of aqueous humor with a prostaglandin analogue (travoprost) to increase the outflow of aqueous humor. It is approved in Australia and is under review in other countries.